ATE286883T1 - Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität - Google Patents

Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität

Info

Publication number
ATE286883T1
ATE286883T1 AT00971423T AT00971423T ATE286883T1 AT E286883 T1 ATE286883 T1 AT E286883T1 AT 00971423 T AT00971423 T AT 00971423T AT 00971423 T AT00971423 T AT 00971423T AT E286883 T1 ATE286883 T1 AT E286883T1
Authority
AT
Austria
Prior art keywords
isoquinoline
5ht1b
5ht1a
combined
receptor activity
Prior art date
Application number
AT00971423T
Other languages
English (en)
Inventor
Laramie Mary Gaster
Thomas Daniel Heightman
Jean-Pierre Pilleux
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926304.8A external-priority patent/GB9926304D0/en
Priority claimed from GB0017880A external-priority patent/GB0017880D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE286883T1 publication Critical patent/ATE286883T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT00971423T 1999-11-05 2000-11-02 Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität ATE286883T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9926304.8A GB9926304D0 (en) 1999-11-05 1999-11-05 Novel compounds
GB0017880A GB0017880D0 (en) 2000-07-20 2000-07-20 Novel compounds
PCT/EP2000/010908 WO2001032626A1 (en) 1999-11-05 2000-11-02 Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity

Publications (1)

Publication Number Publication Date
ATE286883T1 true ATE286883T1 (de) 2005-01-15

Family

ID=26244692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971423T ATE286883T1 (de) 1999-11-05 2000-11-02 Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität

Country Status (10)

Country Link
US (1) US20050239797A1 (de)
EP (1) EP1228043B1 (de)
JP (1) JP2003513075A (de)
AT (1) ATE286883T1 (de)
AU (1) AU1028601A (de)
DE (1) DE60017446T2 (de)
ES (1) ES2234683T3 (de)
PE (1) PE20010956A1 (de)
UY (1) UY26426A1 (de)
WO (1) WO2001032626A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283199A4 (de) * 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd Antagonisten des melanin-konzentrierenden hormons
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315571A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
EP2256106B1 (de) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituierte 1H-Pyrazol-Verbindungen und deren Verwendung als Cyclin-abhängige Kinase (CDK) und Glycogen Synthase Kinase-3 (GSK-3) Modulatoren
AU2005205016B2 (en) * 2004-01-16 2010-07-15 F. Hoffmann-La Roche Ag 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1H-quinazolin-2-one derivatives and the respective 1H-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(D) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-HT) for the treatment of diseases of the central nervous system
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
US7887784B2 (en) 2007-03-21 2011-02-15 University Of Montana 1-[(2′-substituted)-piperazin-1′ -yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
KR101709127B1 (ko) * 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN112480007B (zh) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法
WO2025190395A2 (en) * 2024-03-14 2025-09-18 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932412A (en) * 1970-12-07 1976-01-13 Sandoz, Inc. 1-(4-Hydroxyalkylpiperazino)-isoquinoline nitrates
US3778440A (en) * 1970-12-07 1973-12-11 Sandoz Ag 1-substituted amino-isoquinolines and nitrates thereof
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU732863B2 (en) * 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
WO1998047868A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
CA2313125A1 (en) * 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
WO2000006575A2 (en) * 1998-07-28 2000-02-10 Smithkline Beecham Plc Azabicyclic compounds

Also Published As

Publication number Publication date
DE60017446T2 (de) 2006-03-02
PE20010956A1 (es) 2001-09-15
US20050239797A1 (en) 2005-10-27
JP2003513075A (ja) 2003-04-08
ES2234683T3 (es) 2005-07-01
AU1028601A (en) 2001-05-14
DE60017446D1 (de) 2005-02-17
EP1228043A1 (de) 2002-08-07
EP1228043B1 (de) 2005-01-12
UY26426A1 (es) 2001-05-31
WO2001032626A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
DE60017446D1 (de) Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
MY138836A (en) Quinoline derivatives and their use as 5-ht6 receptor ligands
MY132229A (en) Indole derivatives as 5-ht receptor antagonist
EE200200217A (et) Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
MY119181A (en) Aryl pyrimidine derivatives
SE0003984D0 (sv) Adenosin A3-receptormodulatorer
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE346068T1 (de) Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
TR199902449T2 (xx) Farmakolojik etkin maddeler.
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
DE60140530D1 (de) 5-ht7 rezeptor-antagonisten
BR9406034A (pt) Derivados de imidazoloquinoxalinonas como antagonistas de eaa.
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
BR9911178B1 (pt) Derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenometil)-cefems, bem como preparação farmacêutica e uso dos mesmos
BR9914397A (pt) Derivados da ureidopiperidina como antagonistas seletivos dos receptores nk3 humanos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties